Secondary prevention of diabetic patients with coronary artery disease in cardiac rehabilitation: Risk factors, treatment and target level attainment

Current Medical Research and Opinion

Volumn 25, Issue 4, 2009, Pages 879-890

  Völler, Heinz ^a,f   Reibis, R ^a   Pittrow, D ^b   Jannowitz, C ^c   Wegscheider, K ^d   Karmann, B ^e   Bestehorn, K ^b,c  

^a Klinik am See   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c MSD Sharp and Dohme GmbH   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e Medical Department   (Germany)

^f Rehabilitation Center for Cardiovascular Diseases   (Germany)

Author keywords

Coronary artery disease; Diabetes mellitus; Guideline oriented therapy; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE DISTRIBUTION; AGED; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONFERENCE PAPER; CORONARY RISK; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE REGISTRY; EXERCISE TOLERANCE; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART REHABILITATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; REGISTER; RISK MANAGEMENT; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE; TREND STUDY; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; BEHAVIOR THERAPY; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; COMORBIDITY; CORONARY DISEASE; COUNSELING; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC DIET; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; REFERENCE VALUES; RISK FACTORS; RISK MANAGEMENT; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 67649386579     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902801360     Document Type: Conference Paper

References (44)

1. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136 (Pubitemid 46137814)
2. Franco OH, Steyerberg EW, Hu FB, et al. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med 2007;167:1145 (Pubitemid 46924742)
3. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444 (Pubitemid 23046633)
4. Khaw K-T, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: The European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 2004;141:413-420 (Pubitemid 39281877)
5. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234 (Pubitemid 28350165)
6. Juutilainen A, Lehto S, Ronnemaa T, et al. Type 2 diabetes as a 'coronary heart disease equivalent': an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005;28:2901-2907
7. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393 (Pubitemid 36159355)
8. Gaede P, Lund-Andersen H, Parving H-H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591 (Pubitemid 351214285)
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-713 (Pubitemid 28414300)
10. Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-1762 (Pubitemid 28269185)
11. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:1-10 (Pubitemid 39128338)
12. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J 1998;316:823-828 (Pubitemid 28112428)
13. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239 (Pubitemid 38924592)
14. Smith Jr SC, Feldman TE, Hirshfeld Jr JW, et al. ACC/AHA/ SCAI 2005 guideline update for percutaneous coronary intervention - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention). Catheter Cardiovasc Interv 2006;67:87-112
15. Karoff M, Held K, Bjarnason-Wehrens B. Cardiac rehabilitation in Germany. Eur J Cardiovasc Prev Rehabil 2007;14:18-27 (Pubitemid 46277021)
16. Bestehorn K, Wegscheider K, Völler H. Contemporary trends in cardiac rehabilitation in Germany: patient characteristics, drug treatment, and risk-factor management from 2000 to 2005. Eur J Cardiovasc Prev Rehabil 2008;15:312-318
17. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-1840
18. Bjarnason-Wehrens B, Held K, Hoberg E, et al. Deutsche Gesellschaft für Prävention und Rehabilitation von Herz-Kreislauferkrankungen e.V. (DGPR) in Zusammenarbeit mit der Deutschen Gesellschaft für Rehabilitationswissenschaften e.V. (DGRW) und der Deutschen Gesellschaft für Sportmedizin und Prävention e.V. (DGSP). Deutsche Leitlinie zur Rehabilitation von Patienten mit Herz-Kreislauferkrankungen (DLL-KardReha). Clin Res Cardiol 2007;2:III/1-III/54
19. Ades PA. Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med 2001;345:892-902 (Pubitemid 34940830)
20. Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004;60:135-142 (Pubitemid 38626444)
21. Völler H, Sonntag FJ, Thiery J, et al. Management of high-risk patients with hypertension and left ventricular hypertrophy in Germany: differences between cardiac specialists in the inpatient and outpatient setting. BMC Public Health 2006;6:256 (Pubitemid 44664452)
22. American Diabetes Association. Standards of Medical Care in Diabetes - 2007. Diabetes Care 2007;30:4-41
23. Gottlieb S, Leor J, Shotan A, et al. Comparison of effectiveness of angiotensin-converting enzyme inhibitors after acute myocardial infarction in diabetic versus nondiabetic patients. Am J Cardiol 2003;92:1020-1025 (Pubitemid 37329524)
24. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-1951 (Pubitemid 39447135)
25. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
26. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878 (Pubitemid 34940826)
27. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278 (Pubitemid 41416582)
28. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 2007;93:914-921 (Pubitemid 47122038)
29. Hulten E, Jackson JL, Douglas K, et al. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:1814-1821 (Pubitemid 44455162)
30. Ahmed S, Cannon CP, Murphy SA, et al. Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J 2006;27:2323-2329 (Pubitemid 44453576)
31. Costa J, Borges M, David C, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. Br Med J 2006: bmj.38793.468449.AE (Pubitemid 44480873)
32. Franklin K, Goldberg RJ, Spencer F, et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 2004;164:1457-1463
33. Norhammar A, Malmberg K, Ryden L, et al. Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J 2003;24:838-844 (Pubitemid 36528563)
34. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006;114:2788-2797 (Pubitemid 46018281)
35. Alsheikh-Ali AA, Maddukuri PV, Han H, et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007;50:409-418 (Pubitemid 47096680)
36. Davidson MH, Maccubbin D, Stepanavage M, et al. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006;97:223-228 (Pubitemid 43139240)
37. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626-2632 (Pubitemid 29237448)
38. Goyal A, Mahaffey KW, Garg J, et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J 2006;27:1289-1297 (Pubitemid 43998101)
39. Stranders I, Diamant M, van Gelder RE, et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med 2004;164:982-988 (Pubitemid 38581518)
40. Pischke CR, Weidner G, Elliott-Eller M, et al. Comparison of coronary risk factors and quality of life in coronary artery disease patients with versus without diabetes mellitus. Am J Cardiol 2006;97:1267-1273
41. Banzer JA, Maguire TE, Kennedy CM, et al. Results of cardiac rehabilitation in patients with diabetes mellitus. Am J Cardiol 2004;93:81-84 (Pubitemid 38022039)
42. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-2144 (Pubitemid 34694020)
43. Bartnik M, Malmberg K, Norhammar A, et al. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004;25:1990-1997 (Pubitemid 39486017)
44. Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25:1880-1890